Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.00 USD
+0.05 (0.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $17.01 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.00 USD
+0.05 (0.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $17.01 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Zacks News
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
Integra (IART) Up 8.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook
by Zacks Equity Research
Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Integra LifeSciences (IART) Misses Q1 Earnings Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -20.00% and 0.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain HealthEquity Stock for Now
by Zacks Equity Research
Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.
Bio-Rad Launches Serology Test to Detect Coronavirus Antibody
by Zacks Equity Research
Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.
Why Integra (IART) Could Beat Earnings Estimates Again
by Zacks Equity Research
Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integra Releases Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.
Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods
by Zacks Equity Research
This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.
Here's Why You Should Retain AMN Healthcare (AMN) for Now
by Zacks Equity Research
Investor confidence remains high on AMN Healthcare's (AMN) stock, thanks to solid prospects.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.
Zacks.com featured highlights include: TGNA, IART, PCG, CLGX and ABC
by Zacks Equity Research
Zacks.com featured highlights include: TGNA, IART, PCG, CLGX and ABC
Varian Unveils Proton Treatment Planning Eclipse v16 System
by Zacks Equity Research
The launch of this system is a step forward in Varian's (VAR) commitment toward strengthening its Proton Solutions segment.
5 Recession-Proof PEG Picks Suitable for GARP Investors
by Urmimala Biswas
Here are five GARP stocks to brace your portfolio from recessionary hurdles.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in DexCom's (DXCM) stock, thanks to solid prospects.
Syneos Health Launches Initiative for COVID-19 Patients
by Zacks Equity Research
The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.
IART vs. ABMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. ABMD: Which Stock Is the Better Value Option?
Stellar Codman Surgical Sales Aid Integra Amid Supply Issues
by Zacks Equity Research
Completion of integration activities, scale expansion, product launches, and venturing into faster-growing markets drive Interga's (IART) sales within Codman Surgical.
Why Is Integra (IART) Down 37.3% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Buy Integra LifeSciences Stock Now
by Zacks Equity Research
Investor confidence is high in Integra LifeSciences (IART) stock, thanks to solid prospects.
IART vs. ABMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IART vs. ABMD: Which Stock Is the Better Value Option?
Integra Launches AmnioExcel Placental Allograft Membrane
by Zacks Equity Research
The launch of this product is expected to boost Integra's (IART) OTT segment.
Integra LifeSciences Grows Organically Amid Supply Issues
by Zacks Equity Research
Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.
Integra (IART) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.